- Abrilada is Pfizer’s biosimilar to AbbVie’s blockbuster rheumatoid arthritis drug, Humira. The FDA’s greenlight brings the total number of approved biosimilars to 25.
- Adakveo, designated a breakthrough drug, is the first targeted therapy to treat sickle cell disease. It is made by Novartis.
- Fetroja is Shionogi & Co.’s antibiotic designed to treat complicated urinary tract infections. It is designed for patients age 18 or older who have limited or no alternative treatments.
- Brukinsa is BeiGeine USA’s breakthrough lymphoma treatment. It is designed to treat adult patients with mantle cell lymphoma who have received at least one prior therapy.
- Reblozyl is Celegene’s drug designed to treat anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.
- Vumerity is Biogen and Alkermes’ oral drug designed to treat relapsing forms of multiple sclerosis, a chronic disease that affects the central nervous system.
- Trikafta is Vertex Pharmaceuticals’ breakthrough cystic fibrosis drug, designed to treat a mutation found in 90 percent of the U.S. cystic fibrosis population, or about 27,000 people.
- Xofluza is Genentech’s flu treatment, the first approved antiviral drug designed specifically for patients with a high risk for serious flu complications.
More articles on pharmacy:
Drugmakers could lose $1T in sales and still be most profitable industry, analysis finds
CAR-T costs ‘not sustainable’ for hospitals, researchers say
How Walgreens, CVS see the future of pharmacy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
